Illumina officials said this week that the firm’s Genome Analyzer, the next-generation DNA sequencing instrument it gained through the acquisition earlier this year of Solexa, is exceeding sales expectations and played a key role in the firm’s strong second-quarter results.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.